XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer

Maria Tengström; Arto Mannermaa; Veli-Matti Kosma; Ari Hirvonen; Vesa Kataja

XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer

Anticancer Res. 2014 Jun;34(6):3031-7.

Authors

Maria Tengström¹, Arto Mannermaa², Veli-Matti Kosma², Ari Hirvonen³, Vesa Kataja⁴

Affiliations

¹ Cancer Center, Kuopio University Hospital, Kuopio, Finland Institute of Clinical Medicine, Pathology, University of Eastern Finland, Kuopio, Finland Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland maria.tengstrom@kuh.fi.
² Institute of Clinical Medicine, Pathology, University of Eastern Finland, Kuopio, Finland Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland Imaging Center, Pathology, Kuopio University Hospital, Kuopio, Finland.
³ Finnish Institute of Occupational Health, Helsinki, Finland.
⁴ Cancer Center, Kuopio University Hospital, Kuopio, Finland Institute of Clinical Medicine, Pathology, University of Eastern Finland, Kuopio, Finland Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland.

PMID: 24922669

Abstract

Background: Single nucleotide polymorphisms (SNPs) in a DNA-repair gene, X-Ray repair cross complementing group 1 (XRCC1), have been associated with the survival of patients with breast cancer. We investigated the predictive value of XRCC1 SNP (rs25487) in patients with early breast cancer.

Patients and methods: The XRCC1 rs25487 genotypes of 411 Finnish patients with breast cancer were analyzed by a polymerase chain reaction-restriction fragment length polymorphism-based method. Survival was assessed by Kaplan-Meier method and Cox regression analysis according to the XRCC1 genotypes in specified adjuvant treatment groups.

Results: The rs25487 variant AA genotype was associated with worse breast cancer-specific and overall survival in 238 patients receiving postoperative radiotherapy (p=0.031 and p=0.030, respectively). The AA genotype predicted worse breast cancer-specific survival among 75 patients treated with adjuvant chemotherapy (p=0.047).

Conclusion: The XRCC1 rs25487 genotype may predict the outcome of postoperative radiotherapy and adjuvant chemotherapy in breast cancer.

Keywords: XRCC1; breast cancer; chemotherapy; polymorphism; radiotherapy.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / genetics
Breast Neoplasms / genetics
Breast Neoplasms / mortality*
Breast Neoplasms / therapy
Carcinoma, Ductal, Breast / genetics
Carcinoma, Ductal, Breast / mortality*
Carcinoma, Ductal, Breast / therapy
Carcinoma, Lobular / genetics
Carcinoma, Lobular / mortality*
Carcinoma, Lobular / therapy
Case-Control Studies
Chemotherapy, Adjuvant
Combined Modality Therapy
DNA-Binding Proteins / genetics*
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local / genetics
Neoplasm Recurrence, Local / mortality*
Neoplasm Recurrence, Local / therapy
Neoplasm Staging
Polymerase Chain Reaction
Polymorphism, Genetic / genetics*
Polymorphism, Restriction Fragment Length
Postoperative Period
Prognosis
Prospective Studies
Radiotherapy Dosage
Survival Rate
X-ray Repair Cross Complementing Protein 1

Substances

Biomarkers, Tumor
DNA-Binding Proteins
X-ray Repair Cross Complementing Protein 1
XRCC1 protein, human